Bellevue Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bellevue Group’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-39,207	Closed	-$4.65M	–	187
2022 Q1	$4.65M	Buy	39,207 +1,200	+3%	+$150K	0.05%	119
2021 Q4	$5.24M	Buy	38,007 +20,507	+117%	+$2.61M	0.05%	125
2021 Q3	$2.43M	Sell	17,500 -18,500	-51%	-$2.31M	0.02%	144
2021 Q2	$3.5M	Hold	36,000	–	–	0.03%	136
2021 Q1	$2.46M	Buy	36,000 +23,500	+188%	+$1.9M	0.03%	136
2020 Q4	$1.07M	Sell	12,500 -12,000	-49%	-$1.02M	0.01%	154
2020 Q3	$1.59M	Buy	+24,500	New	+$1.61M	0.02%	147
2020 Q2	–	Sell	-24,800	Closed	-$844K	–	232
2020 Q1	$844K	Buy	24,800 +2,100	+9%	+$96K	0.02%	144
2019 Q4	$1.24M	Buy	+22,700	New	+$1.12M	0.02%	148

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group's BHVN Position: Q2 2022 in Review

Bellevue Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 39,207 shares — an estimated $4.65M sold.

Bellevue Group first reported a position in BHVN in Q4 2019 and held it in 9 quarters. The position peaked at $5.24M in Q4 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Bellevue Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Bellevue Group sold 39,207 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $4.65M.
Bellevue Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2019 and held it in 9 quarters.
Bellevue Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $5.24M in Q4 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Bellevue Group's 13F filing for Q2 2022, filed 11 Aug 2022.